We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.08 | 14.16 | 13.96 | 14.15 | 7,051,252 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Weiss Amir |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Accounting Officer / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Ordinary Shares (1) | 14391.41 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Restricted Share Units | (2) | (2) | Ordinary Shares (1) | 14258 | (3) | D | |
Restricted Share Units | (4) | (4) | Ordinary Shares (1) | 9657 | (3) | D | |
Restricted Share Units | (5) | (5) | Ordinary Shares (1) | 4809 | (3) | D | |
Restricted Share Units | (6) | (6) | Ordinary Shares (1) | 981 | (3) | D | |
Stock Options (right to buy) | (7) | 3/2/2028 | Ordinary Shares (1) | 10002 | $19.16 | D | |
Stock Options (right to buy) | (8) | 3/3/2027 | Ordinary Shares (1) | 7755 | $34.70 | D | |
Stock Options (right to buy) | (9) | 3/17/2026 | Ordinary Shares (1) | 5003 | $53.50 | D | |
Stock Options (right to buy) | (10) | 3/12/2025 | Ordinary Shares (1) | 3752 | $60.21 | D | |
Stock Options (right to buy) | (11) | 3/11/2024 | Ordinary Shares (1) | 1501 | $48.76 | D |
Remarks: Exhibit 24 - Power of Attorney |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Weiss Amir C/O 124 DVORA HANEVI'A ST. TEL AVIV, L3 6944020 | Chief Accounting Officer |
Signatures | ||
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss | 12/6/2021 | |
**Signature of Reporting Person | Date |
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions